Ionis Pharmaceuticals Will Present New Subgroup Analyses From Ionis And AstraZeneca's Phase 3 NEURO-TTRansform Study Of Wainua (Eplontersen) At 2024 International Symposium On Amyloidosis

AstraZeneca PLC +1.37%
Ionis Pharmaceuticals, Inc. -0.45%

AstraZeneca PLC

AZN

203.49

+1.37%

Ionis Pharmaceuticals, Inc.

IONS

74.79

-0.45%

WAINUA was approved by the FDA in December 2023 for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.